Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the life sciences tools & services industry, including Illumina (NASDAQ:ILMN) and its peers.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the life sciences tools & services stocks, including 10x Genomics (NASDAQ:TXG) and its peers.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at drug development inputs & services stocks, starting with West Pharmaceutical Services (NYSE:WST).
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 13.8%. This drop is a far cry from the S&P 500’s 5.3% ascent.
Exciting developments are taking place for the stocks in this article.
They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Let's delve into the developments on the US markets in the middle of the day on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Looking for the S&P500 stocks that are experiencing notable gaps on Friday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 9.2% year on year to $766.5 million. The company’s full-year revenue guidance of $3.05 billion at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $1.84 per share was 22% above analysts’ consensus estimates.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Shares of healthcare products company West Pharmaceutical Services (NYSE:WST)
jumped 22.9% in the afternoon session after the company reported strong second-quarter 2025 financial results and raised its full-year outlook.
West Pharmaceutical raised its 2025 EPS and sales guidance after Q2 earnings and revenue topped estimates, fueled by strong demand for high-value products.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Thursday. Discover the gap up and gap down stocks in the S&P500 index.
